Acerta Pharma BV

Quick facts

Phase 3 pipeline

• Acalabrutinib (ACP-196) · Oncology
  Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling.

Phase 2 pipeline

• acalabrutinib and pembrolizumab combination
• ACP-196 · Oncology
  BTK inhibitor
• AZD9150 · Oncology
  AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein.

Phase 1 pipeline

• Acalabrutinib in combination with BR · Oncology
  BTK inhibitor
• Acalabrutinib in combination with VR · Oncology
  BTK inhibitor
• ACP-319
• AZD5153 · Oncology
  AZD5153 is a selective BET bromodomain inhibitor that disrupts the interaction between bromodomains and acetylated histones, leading to changes in gene expression.
• Microtracer [14C]ACP-196
• SmartPill®

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Acerta Pharma BV portfolio CI brief
• Acerta Pharma BV pipeline updates RSS